A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Cancer

Volumn 103, Issue 12, 2005, Pages 2584-2589

  Markovic, Svetomir N ^a   Geyer, Susan M ^a   Dawkins, Fitzroy ^b   Sharfman, William ^c   Albertini, Mark ^d   Maples, William ^d   Fracasso, Paula M ^e   Fitch, Tom ^f   LoRusso, Patricia ^a   Adjei, Alex A ^a   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c University of Wisconsin ^*

^d MAYO CLINIC   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bortezomib; General; Metastatic malignant melanoma; Proteosome inhibitor

Indexed keywords

BORTEZOMIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; ILEUS; INFECTION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 20444364475     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21108     Document Type: Article

References (26)

1. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol. 2002;6:493-500.
2. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 2000;14: 1276-1283.
3. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638-2645.
4. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 2001;28:613-619.
5. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
6. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511.
7. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274:1652-1659.
8. Plemper RK, Hammond AL. Protein degradation in human disease. Prog Mol Subcell Biol. 2002;29:61-84.
9. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
10. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773-785.
11. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993;4:219-229.
12. Gillessen S, Groettup M, Cerny T. The proteasome, a new target for cancer therapy. Onkologie. 2002;25:534-539.
13. Sakamoto KM. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Genet Metab. 2002;77:44-56.
14. Wojcik C. Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med. 2002;6:25-48.
15. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev. 2003;29(Suppl 1):33-39.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
17. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
18. Goy A, Hart S, Pro B, et al. Report of a phase II study of proteasome inhibitor bortezomib (VELCADE™) in patients with relapsed or refractory indolent or aggressive lymphomas [abstract]. Blood. 2003;102:627.
19. Assouline S, Belch A, Sehn L, et al. A phase II study of bortezomib in patients with mantle cell lymphoma [abstract]. Blood. 2003;102:3358.
20. Stevenson JP, Nho CW, Johnson SW, et al. Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a phase IV pharmacodynamic trial [abstract]. J Clin Oncol. 2004;22:652s.
21. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001;82:110-122.
22. Cusack JC Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535-3540.
23. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001;100:11-17.
24. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma. 2002;3:49-55.
25. Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. Molecular pathways that modify tumor radiation response. Am J Clin Oncol. 2001;24:481-485.
26. Russo SM, Tepper JE, Baldwin AS Jr., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50: 183-193.